Business Context and Reporting Period
Company: Pro-Pharmaceuticals, Inc. (d/b/a Galectin Therapeutics Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: A development-stage biotechnology company focused on discovering and developing therapeutics targeting Galectin receptors to enhance cancer treatments (specifically colorectal cancer) and treat liver, microbial, and inflammatory diseases. The company has no commercial products and has not generated revenue since inception.
Key Financial Metrics
| Metric | 2009 (in thousands) | 2008 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,462) | $(3,151) |
| Net Loss Applicable to Common Stockholders | $(9,419) | $(3,390) |
| Research & Development Expenses | $1,110 | $1,774 |
| General & Administrative Expenses | $4,983 | $3,552 |
| Cash and Cash Equivalents (End of Period) | $251 | $318 |
| Accumulated Deficit | $(47,715) | $(38,550) |
| Warrant Liabilities | $1,633 | $55 |
Note: The company reported a significant non-cash loss of $1.374 million in 2009 due to the change in fair value of warrant liabilities, compared to a gain of $2.145 million in 2008.
Material Changes vs. Prior Period
- Operating Loss Increase: Net loss increased by approximately 137% year-over-year, driven primarily by a $1.374 million loss on the change in fair value of warrant liabilities and increased General and Administrative (G&A) expenses.
- G&A Expense Surge: G&A expenses rose 40% to $4.983 million, attributed to increased stock-based compensation ($827,000), severance obligations for the former CEO ($765,000), and business development costs ($172,000).
- R&D Expense Reduction: R&D expenses decreased 37% to $1.110 million due to cost containment measures and the cessation of certain Phase II trials (biliary and colorectal cancer) due to financial constraints.
- Liquidity Position: Unrestricted cash decreased to $251,000. The company raised $4.02 million in net proceeds during 2009 through the issuance of Series B-1 and Series B-2 redeemable convertible preferred stock.
- Stock Listing: Common stock was delisted from the NYSE Alternext US in January 2009 and now trades on the OTC Bulletin Board.
Guidance, Outlook, Risks, and Contingencies
Going Concern and Liquidity
The auditors have expressed substantial doubt about the company's ability to continue as a going concern. Management estimates that with cash on hand ($251,000) and proceeds from subsequent Series B-2 closings in early 2010 ($630,000 net), the company has sufficient funds to operate only until April 2010. Failure to raise additional capital by this date may force the company to curtail operations, cease operations, or seek bankruptcy protection.
Regulatory and Product Outlook
The lead product candidate, DAVANAT, requires a Phase III trial to demonstrate superiority to the standard of care for late-stage colorectal cancer before an NDA can be approved. The company plans to initiate this trial upon securing additional funding. No revenue is expected for several years, if at all.
Legal Contingencies
- Summer Street Research Partners: The company is defending a lawsuit alleging breach of contract regarding placement fees. The company believes the claim is without merit, but an adverse decision could result in material cash damages.
- Former CEO Litigation: A lawsuit regarding intellectual property filed by the former CEO was dismissed by the court in July 2009.
- Severance Obligations: A $1.0 million severance payment to the former CEO is contingent on specific milestones (FDA approval, significant funding, or relisting). This amount is not currently accrued but would become payable immediately in the event of bankruptcy.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure financing before the April 2010 deadline to avoid insolvency.
- Warrant Liability Volatility: Assess the impact of fair value accounting on warrant liabilities, which caused significant non-cash losses in 2009 and could distort future earnings.
- Dilution Risk: Review the terms of Series B-1 and B-2 preferred stock and outstanding warrants (over 50 million warrants outstanding), which represent massive potential dilution to common shareholders.
- Phase III Trial Funding: Confirm if the company has secured the capital necessary to fund the required Phase III clinical trial for DAVANAT.
- Legal Exposure: Monitor the status of the Summer Street Research Partners litigation for potential cash outflows.